← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Immunext, Inc.
Lebanon, NH
$16,466,741
Total funding
8
Grants
Funding over time
peak $2.3M · FY2012–23$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$16,466,741 · 8
By mechanism
R44$13,326,570 · 4
R42$1,949,257 · 1
R41$890,914 · 2
R43$300,000 · 1
Investigators at Immunext, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease$1,004,563
R44 · FY2019 · AI
Safe and effective anti CD154 antibodies for therapeutic intervention$1,000,000
R44 · FY2015 · AI
Safe and effective anti CD154 antibodies for therapeutic intervention$998,002
R44 · FY2013 · AI
Targeting leukocyte metabolism to treat human autoimmune disease$996,128
R44 · FY2019 · AI
Targeting leukocyte metabolism to treat human autoimmune disease$995,802
R44 · FY2018 · AI
Targeting leukocyte metabolism to treat human autoimmune disease$995,802
R44 · FY2020 · AI
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease$995,160
R42 · FY2014 · AI
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease$992,040
R44 · FY2018 · AI
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease$991,804
R44 · FY2017 · AI
Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases$990,946
R44 · FY2021 · AI
Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases$974,853
R44 · FY2022 · AI
Safe and effective anti CD154 antibodies for therapeutic intervention$962,696
R44 · FY2014 · AI
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease$954,097
R42 · FY2015 · AI
Safe and effective anti CD154 antibodies for therapeutic intervention$912,191
R44 · FY2016 · AI
Safe and effective anti CD154 antibodies for therapeutic intervention$912,191
R44 · FY2017 · AI
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease$300,000
R41 · FY2012 · AI
Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease$300,000
R41 · FY2013 · AI
VISTA: A Novel Therapeutic Target That Negatively Regulates Immunity$300,000
R43 · FY2012 · AI
Targeting the checkpoint regulator VISTA for treatment of inflammatory disease$299,938
R44 · FY2017 · AI
Targeting leukocyte metabolism to treat human autoimmune disease$299,502
R44 · FY2018 · AI